To summarize the latest advancements in rosacea treatments targeting the neuro-vascular-immune triad.
Approach:
Key Findings:
Abnormal activation of the neuro-vascular-immune triad is a key pathological mechanism in rosacea.
Emerging therapies targeting this triad lack large-scale randomized controlled trials.
Optimal dosing regimens and treatment durations for these therapies remain unclear.
Interpretation:
Future studies should focus on strengthening basic investigations, exploring combined therapeutic strategies, and developing personalized approaches for effective long-term control of rosacea.
Limitations:
Lack of large-scale randomized controlled trials for the discussed therapies.
Uncertainty regarding optimal dosing regimens and treatment durations.
Conclusion:
This review highlights the need for further research to enhance treatment efficacy and personalization in rosacea management.
